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Abstract
Purpose: To evaluate the cardiac toxicity of radiotherapy (RT) in breast cancer (BC) patients employing myocardial
perfusion imaging (MPI) with Tc-99 m Tetrofosmin - single photon emission computer tomography (T-SPECT).
Materials and methods: We studied 46 BC female patients (28 patients with left and 18 patients with right BC)
treated with postoperative RT compared to a control group of 85 age-matched females. The median time of RT to
SPECT was 40 months (6-263).
Results: Abnormalities in the summed stress score (SSS) were found in 54% of left BC patients, 44.4% of right BC
patients, and 32.9% of controls. In left BC patients there were significantly more SSS abnormalities compared to
controls (4.0 ± 3.5 vs 2.6 ± 2.0, p = 0.05) and possible trend of increased abnormalities of right BC patients (3.7 ±
3.0 vs 2.6 ± 2.0, p = 0.14). Multiple regression analysis showed more abnormalities in the MPI of left BC patients
compared to controls (SSS, p = 0.0001); Marginal toxicity was also noted in right BC patients (SSS, p = 0.045). No
additional toxicity was found in patients that received adjuvant cardiotoxic chemotherapy. All T-SPECT
abnormalities were clinically silent.
Conclusion: The study suggests that radiation therapy to BC patients result in MPI abnormalities but without
apparent clinical consequences.
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Introduction
Breast cancer (BC) is the most common cancer in
women [1]. Postsurgical radiation therapy offers sub-
stantial benefits in appropriately selected patients with
BC [2-4]. Because radiation techniques have improved
over time, the risk of death from ischemic heart disease
associated with radiation for BC has substantially
decreased over time [5]. The delivery of radiation is
based on the anatomic volumes from CT simulation
scans thus all tissue at risk must be meticulously deli-
neated to allow the dose of radiation to be sculpted to
the target structures (ie breast, chest wall ± regional
nodes) while minimizing dose to the normal structures
(ie heart and lung). Using CT simulators, modern-day
linear accelerators, computerized treatment planning
modalities, and on-board imaging techniques, the thera-
peutic ratio for radiation therapy has markedly
improved, whereas the potential for side effects has
diminished significantly. However, radiation techniques
that include both breast and regional lymph nodes,
result in a higher probability of heart complications
compared with tangential irradiation of the breast only
[6]. In any event, radiotherapy for left sided BC may
represent an independent risk factor in the long-term
development of ischemic heart disease [7], and patients
who receive high irradiation dose-volumes may exhibit * Correspondence: csioka@yahoo.com
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cular damage to the heart [8].
Myocardial perfusion abnormalities both at rest and
after stress are reliable predictors of subsequent cardiac
events in patients with ischemic heart disease [9,10]. In
order to better understand the cardiac toxicity of mod-
ern radiation therapy, we compared myocardial perfu-
sion imaging (MPI) defects in BC patients who received
radiation therapy to MPI defects in age-matched women
with no prior radiotherapy.
Patients and methods
Patients
Forty six female patients with primary BC that had been
treated with postoperative adjuvant radiation therapy
(RT) from 1998 to 2010 were subjected after stress and
at rest to MPI, employing Tc-99 m Tetrofosmin - single
photon emission computer tomography (T-SPECT). All
patients at the time of the test were in remission and
none had any history or symptoms of coronary artery
(CAD) or other heart disease. Among them, 28 patients
had prior RT to the left and 18 patients to the right-
breast area. Furthermore, 85 age-matched control
females with no medical history of cancer or RT or
known CAD were subjected to diagnostic MPI with T-
SPECT. These control individuals were females that
were referred for T-SPECT because of non-specific
complaints of various type chest wall pains, palpitations,
or shortness of breath, and negative clinical cardiology
examination and normal ECG. All participants were
interviewed in person using a structured questionnaire.
Major cardiac risk factors including age, smoking,
hypertension, diabetes, dyslipidemia and family history
of cardiovascular disease were recorded. Arterial hyper-
tension was documented when systolic blood pressure
(BP) was ≥ 140 mmHg or diastolic BP ≥ 90 mmHg or
when individuals were receiving anti-hypertensive drugs
for previously established hypertension. Smoking, active
or ceased within the last 3 months, was considered as
current. Diabetes mellitus was considered as present if
fasting glucose was > 126 mg/dl or the individual was
treated with antidiabetic medication. Dyslipidemia was
defined as fasting cholesterol > 220 mg/dl or the indivi-
dual was on current treatment with specific agents.
Information concerning their BC history (i.e.,s i d eo f
radiation therapy, age during the therapy, previously use
of chemotherapy etc) was collected. The protocol was
approved by the Hospital’s Clinical Research Committee
and all studied individuals gave informed consent to the
examination.
Radiation therapy
The treatment planning was performed using a 3D
treatment planning system (Pinnacle version 7.4).
Treatment plans were normalized at the International
Commission on Radiation Units and Measurements
(ICRU) reference point of the breast Planning Target
Volume (PTV). Every patient was immobilized in a
s u p i n ep o s i t i o na n dp l a c e do na ni n c l i n e db r e a s tb o a r d
in an optimized treatment position. Patients were simu-
lated in a large-bore CT simulator with 8 mm slice
separation. Missing tissue compensation filters (wedges)
were used when it was necessary. The heart was con-
toured using the soft-tissue shadow at one slice below
the inferior cut of the right pulmonary artery crossing
the midline. After delineation of the target and organs
at risk, CT data were transferred to the treatment plan-
ning system.
For the tangential field technique, two 2D-radio-
graphic based parameters related to volumetric heart
dose were measured: the Maximum Heart Distance
(MHD), i.e. the maximum distance of the heart contour
to the medial field end, as can be seen on a beam’se y e
view of the mediolateral tangential field and the Maxi-
mum Heart Length (MHL), i.e. the maximum length of
the heart in the tangential fields. MHD and MHL were
used to estimate the volume of heart receiving high
doses using tangential fields. Three dimensional dose
distributions and DVHs of PTV and heart were
analyzed.
Τhe irradiation was delivered with two tangential
fields (a medial and a lateral one) with a linear accelera-
tor (6 MV). According to the type of operation (breast
conserving surgery or mastectomy) the whole breast
with or without the chest wall was included in the treat-
ment fields. The irradiation was delivered in 30 fractions
over a 6-week period. The total prescribed dose was 60
Gy (50 Gy to the PTV and 10 Gy as a boost to the
tumor bed). The daily dose was 2 Gy. According to the
pathology report, radiotherapy was given to the axillary
and internal mammary lymph nodes. These areas if trea-
ted were included in the tangential fields. Approximately
2 cm of lung between the medial border of the field and
the chest wall, where is considered appropriate to pro-
vide an adequate field margin for chest wall irradiation,
was included in our fields. The breast PTV was outlined
on each CT-slice and defined according to ICRU-62
guidelines. The dorsal edges of both beams were made
coplanar to decrease the amount of lung tissue
irradiated.
Τhe mean breast volume was 667.1 cm
3 (range 503-
808 cm
3) and the mean heart dose was on average 774.3
cGy (range 484.5-1095.5 cGy). Percentage volume (PV)
of heart at different dose levels correlated fairly with
MHD (cm) as the following relationships: PV20 = 5.4
MHD - 0.3 (R = 0.94); PV40 = 4.0 MHD - 0.6 (R =
0.89). The percentage volume of the heart at 20% and
40% of the total dose was about 4.7 times the MHD
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mated 4.8 times the mean MHD value (1.62 cm). The
mean MHL value was 4.8 cm for the whole treatment
and 8.3 cm for the 25 sessions (boost sessions not
included). Parameters related to heart were only mea-
sured for left breast irradiation.
SPECT MPI
All study individuals were subjected prior and after
stress to T-SPECT using a 1-d imaging protocol. None
of the patients or the control individuals had gated-
SPECT. Stress protocol was either pharmacological
(dipyridamole or dobutamine) or with dynamic exercise
(Bruce protocol treadmill exercise test) according to
local practice and clinical indication. Stress protocol and
imaging was performed according to published guide-
lines [11]. An electrocardiograph was recorded at rest
and continuously monitored during stress.
All participants were injected with 8 mCi Tc-99m-
tetrofosmin bolus after stress and 20 mCi at rest,
flushed with normal saline, and 30 - 40 minutes later
the SPECT images were acquired. All studies were com-
pleted with a 90°-angled dual-head camera, using a low-
energy, all-purpose collimator with 64 stops and 25 s
per projection (30 projection/head) over a 180° arc.
Acquisition was obtained with a matrix size of 64 × 64
and with a 15% symmetric window at 140 keV. The
method of reconstruction consisted of filter back projec-
tion (filter butterworth, cut-off frequency 0.4, power 10).
No attenuation correction was used.
Two nuclear medicine specialists, blinded to the parti-
cipant’s medical condition, visually evaluated the MPI
using both a 19 segment [12] and the 17 segment [13]
polar maps for the left ventricle. Both MPI polar maps
had identical results. Each segment was scored on a
scale of 0 to 5 according to the severity of the myocar-
dial perfusion deficit. If there was no decreased myocar-
dial activity it was scored 0, for mildly activity it was
scored 1, for mild to moderate decreased activity as 2,
for moderately to severely decreased activity as 3, for
severely activity as 4 and with absent tracer activity as 5
points. Thus, the individual scores of perfusion defects
within each 20 segments at rest and during stress were
combined and provided the summed rest score (SRS)
and summed stress score (SSS). According to the
summed stress score the myocardial ischemia was
graded as mild (4-8), moderate (9-13), and severe (> 13)
[14]. Furthermore, the difference of the two scores (S-
RSS) and myocardial anterior wall summed stress score
(ASSS) were evaluated as well.
Statistical analysis
The analyzed MPI scores of BC patients that were irra-
diated in the left side were compared to those that were
irradiated in the right side. In addition, comparison was
made between irradiated patients and control indivi-
duals. Separate comparisons were made between left
and right BC patients with the control group of 85 indi-
viduals. The role of chemotherapy, time elapsed from
RT, breast type operation and cardiovascular risk factors
with MPI scores were also analyzed.
The results are shown as mean ± SD. The differences
between the groups were tested for significance using
the Student’s t-test for independent samples. Stepwise
multiple regression analysis was performed to examine
variables independently associated with SSS, SRS and
ASSS after controlling for cardiovascular risk factors.
Left or right BC radiotherapy versus controls and left
versus right BC radiotherapy were included in the
model, assumed to be independent variables. P ≤ 0.05
was considered as statistically significant. Data were ana-
lyzed with the SPSS 13.0 for windows program package.
Results
The physical characteristics of patients and control
group that were matched for age are shown in Table 1.
There were no statistical differences in the age of the
BC patients of either subgroup (left or right BC) or con-
trol group at the time of the SPECT. The median time
from BC irradiation to SPECT was 35 months (range, 6-
142) for the patients with left BC and 41 months (range
6-263) for the group with right BC. Among the 46 BC
patients, 26 had radical mastectomy (17 in left BC
group and 9 in right BC group), and 20 patients had
only tumor removal without mastectomy (11 patients in
left and 9 patients in right breast). In 16 of the 29
patients who received adjuvant chemotherapy the drug
regimen included a cardiotoxic agent (either epirubicin
or adriamycin). Comparison of SPECT-MPI results in
patients that either received adjuvant cardiotoxic che-
motherapy or not showed no significant differences
among the two groups (Table 2).
Normal MPI scores were observed in 13/28 (46.4%) of
left BC patients, 10/18 (55.6%) of right BC patients, and
57/85 (67.1%) of control subjects. Among left BC
patients 12/28 (42.9%) had mild, 3/28 (10.7%) had mod-
erate, and none had severe myocardial ischemia on MPI.
In the right BC patients 6/18 (33.3%) had mild, 2/18
(11.1%) moderate and none had severe myocardial
ischemia. Among the control individuals 28/85 (32.9%)
had mild and none had either moderate or severe myo-
cardial ischemia on MPI. The MPI scores in patients
with BC in comparison to the control individuals
showed increased values of the summed stress score in
patients which reached marginal statistical significance
only in the left BC patients (Table 3). Comparison of
scores between left and right BC patients showed no
statistically significant diff e r e n c e sb u tat r e n dt o w a r d s
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left-sided BC.
There were significantly more people in the control
group with risk factors for cardiovascular disease such
as hypertension, hypercholesterolemia and positive
family history of heart disease compared to patient
groups (Table 4). After controlling for cardiovascular
risk factors, multiple regression analysis demonstrated
significant more abnormalities in the SPECT of left BC
patients compared to controls in all myocardial perfu-
sion imaging scores evaluated (Table 5). In the right BC
patients there were significantly increased myocardial
SPECT abnormalities detected by the summed stress
score but not with the other perfusion imaging scores.
Comparison between left and right BC patients showed
no statistical differences between the two groups.
Discussion
Radiation therapy is an integral component in the multi-
disciplinary management of BC. It has been used for
decades to reduce the risk of local-regional recurrence
[2]. Adjuvant radiotherapy has also been shown to
improve overall survival in patients with advanced-dis-
ease stages if the radiation-induced heart disease
remains minimal [15]. It is a well known fact that
adjuvant chest wall/breast irradiation might be asso-
ciated with long-term cardiac toxicity, and in the past, a
significantly increased rate of non-BC deaths have been
reported after RT of left-BC patients [16]. Most of the
patients included in these older retrospective analyses
were irradiated in 1950s to 1970s, and the increased rate
of cardiac mortality was caused by the use of obsolete
treatment techniques. By implementation of modern
treatment and planning techniques in clinical practice
the dose exposure of the heart can be reduced signifi-
cantly, something anticipated to result in decreased car-
diac mortality [17-19]. Thus, it is necessary to protect
the heart as much as possible, in order to prevent unne-
cessary cardiac morbidity [20]. However, breast radiation
therapy may still represent a risk factor for cardiovascu-
lar disease since some exposure of the heart is unavoid-
able [21]. Radiation effects to the myocardium are
predominantly related to inflammatory changes in the
microvasculature, resulting in ischemia, fibrosis and cor-
onary atherosclerosis [22].
I nt h ep r e s e n ts t u d yw ef o u n ds i g n i f i c a n tc h a n g e si n
the myocardial perfusion imaging with T - SPECT of
the irradiated BC patients compared to age-matched
control individuals. These changes in the multivariate
analysis after controlling for the cardiovascular risk
Table 1 Physical characteristics of patients with left and right breast cancer and control individuals
Left Breast
Cancer
N=2 8
Right Breast
Cancer
N=1 8
All Breast Cancer patients
N=4 6
Control individuals
N=8 5
Mean age (SPECT) 59.93 ± 10.57
(41-79)
57.50 ± 9.34
(40-78)
58.97 ± 10.08
(40-79)
58.72 ± 9.72
(40-80)
Body weight (kg)
(SPECT)
70.39 ± 10.66
(52-95)
72.94 ± 10.70
(53-95)
71.39 ± 10.63
(52-95)
71.72 ± 10.81
(40-105)
Mean age (RT) 56.46 ± 10.91
(41-78)
53.17 ± 8.53
(36-71)
55.17 ± 10.08
(36-78)
_
Median time from RT to SPECT (months) 35 (6-142) 41 (6-263) 40 (6-263) _
Type of breast surgery
(M/O)
M: 17/28 (60.7%)
O: 11/28 (39.3%)
M: 9/18 (50.0%)
O: 9/18 (50.0%)
M: 26/46 (56.5%)
O: 20/46 (43.5%)
_
Chemotherapy 17/28 (60.7%) 12/18 (66.7%) 29/46 (63.0%) _
Cardiotoxic
Chemotherapy
11/28 (39.3%) 5/18 (27.8%) 16/46 (34.8%) _
RT: radiotherapy; Cardiotoxic chemotherapy: Drug combination that included adriamycin or epirubicin; M: Total mastectomy; O: Ongectomy.
Table 2 Comparison of T-SPECT results in breast cancer patients that either received (Yes) or not (No) cardiotoxic
adjuvant chemotherapy.
MPI Left Breast
Cancer
Right Breast
Cancer
All Breast
Cancer
Yes No p Yes No p Yes No p
SSS 2.9 ± 3.5 4.7 ± 3.5 0.34 5.2 ± 2.4 3.1 ± 3.1 0.31 3.6 ± 3.3 4.0 ± 3.4 0.83
SRS 1.2 ± 1.9 2.0 ± 2.6 0.46 1.2 ± 1.6 0.6 ± 0.6 0.32 1.2 ± 1.7 1.4 ± 2.1 0.97
ASSS 1.8 ± 3.6 3.1 ± 3.4 0.45 3.6 ± 0.5 1.1 ± 1.3 0.32 2.4 ± 3.1 2.2 ± 2.8 0.74
S-RSS 1.7 ± 1.9 2.6 ± 2.6 0.40 4.0 ± 3.5 2.5 ± 2.7 0.60 2.4 ± 2.6 2.6 ± 2.6 0.79
Cardiotoxic chemotherapy included Adriamycin in 2 patients and Epirubicin in 14 patients; MPI: myocardial perfusion imaging; SSS: summed stress score; SRS:
summed rest score; ASSS: anterior wall stress score; S-RSS: the difference of SSS minus the SRS.
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hyperlipidemia and family history were significantly
more pronounced in the left BC patients, where the
summed stress score was predominantly reduced fol-
lowed by the summed rest score and the anterior wall
stress score. In addition, the right BC patients were also
affected to a lower degree with only the summed stress
score showing a marginally significantly reduction com-
pared to controls. However, although all these changes
in the left and right BC patients were statistically signifi-
cant, they were clinically silent and not requiring further
action at the time of the evaluation. Even though the
clinical consequences of the detected SPECT abnormal-
ities were probably insignificant, further large prospec-
tive clinical trials should more accurately assess the
toxicity of radiation therapy to BC patients. Our study is
in accordance with some prospective studies that exam-
ined patients with left BC prior and after radiotherapy.
For example, an early prospective study in 12 patients
demonstrated myocardial perfusion deficits in 50% of
patients 1 year post radiotherapy [23]. Several other
more recent prospective studies have reported myocar-
dial perfusion deficits in irradiated left sided BC [24-29].
The findings of some of these studies indicated that the
perfusion deficits may appear as early as 6 months post
radiotherapy and may involve a large percentage of
patients (up to 60%) [24,25]. This is in accordance with
our findings that showed no relation between the SSS
and time elapsed from radiotherapy to T-SPECT. In
addition, these perfusion defects may persist for several
years and they may have minimal [27,28], unknown
[26], or clinically relevant long-term functional conse-
quences [30]. None of our patients had clinically signifi-
cant alterations requiring further investigation apart
from close observation.
A recently published study reported that for the per-
iod 1977-2001 in Denmark the mean heart dose aver-
aged around 6 Gy for left-sided and 2-3 Gy for right-
sided radiotherapy and in Sweden decreased from 12.0
to 7.3 Gy for left-sided and from 3.6 to 3.2 Gy for right-
sided radiotherapy [31]. Our estimated mean heart dose
of 7.7 Gy for left-sided irradiated patients was similar to
those observed in the above countries. Other previous
studies indicated no cardiotoxicity of radiotherapy in BC
patients independently of the site of radiation. Thus, a
large retrospective study in 48,353 women with BC,
radiotherapy did not increase the risk of myocardial
infarction regardless of type of surgery, tumor laterality,
or history of cardiac risk factors or heart disease, for at
least 10 years follow up [32]. No significant radiation-
induced toxicity was also reported in 2 randomized
trials of BC patients treated with or without
Table 3 Comparison of myocardial perfusion imaging
scores in patients with left/right breast cancer and
controls (t-test for independent samples, equal variances
not assumed).
MPI LBC
N=2 8
RBC
N=1 8
C
N=8 5
LBC
vs
RBC
LBC
vs
C
RBC
vs
C
SSS 4.0 ± 3.5
(0-13)
3.7 ± 3.0
(0-10)
2.6 ± 2.0
(0-8)
p = 0.78 p = 0.05* p = 0.14
SRS 1.7 ± 2.3
(0-7)
0.8 ± 1.0
(0-4)
1.1 ± 1.3
(0-5)
p = 0.07 p = 0.14 p = 0.40
ASSS 2.6 ± 3.5
(0-13)
1.8 ± 1.6
(0-4)
1.7 ± 1.5
(0-6)
p = 0.28 p = 0.18 p = 0.82
S-RSS 2.3 ± 2.4
(0-9)
2.9 ± 2.9
(0-9)
1.5 ± 1.6
(0-7)
p = 0.43 p = 0.14 p = 0.06
MPI: myocardial perfusion imaging; LBC: left breast cancer patients; RBC: right
breast cancer patients; C: Control individuals; SSS: summed stress score; SRS:
summed rest score; ASSS: anterior wall stree score; S-RSS: the difference of
SSS minus the SRS; *: p ≤ 0.05.
Table 4 Cardiovascular risk factors in patients with left and right breast cancer (mean value ± standard deviation).
Risk factor Left Breast
Cancer
Right Breast
Cancer
Control individuals LBC vs Control RBC vs Control
Smoking 2/28 (7.1%) 4/18 (14.3%) 12/85 (14.1%) p = 0.27 p = 0.46
HTN 14/28 (50.0%) 6/18 (21.4%) 54/85 (63.5%) p = 0.22 p = 0.024*
DM 7/28 (25.0%) 4/18 (14.3%) 15/85 (17.6%) p = 0.51 p = 0.76
HL 10/28 (35.7%) 9/18 (32.1%) 49/85 (57.6%) p = 0.05* p = 0.57
Family
History
5/28 (17.9%) 5/18 (17.9%) 39/85 (45.9%) 0.003** 0.15
HTN: hypertension; DM: diabetes mellitus; HL: hyperlipidemia; LBC: Left breast cancer; RBC: Right breast cancer; *: p ≤ 0.05; **: p ≤ 0.01
Table 5 Multiple regression analysis in 46 female
patients with breast cancer and 85 control females after
myocardial perfusion imaging with T - SPECT).
Independent
variable
SSS
Beta
p SRS
Beta
p ASSS
Beta
p
Left BC versus
controls
-0.26 0.0001** -0.02 0.05* -0.19 0.05*
Right BC versus
controls
-0.21 0.045* 0.04 0.68 -0.06 0.59
Left BC versus
Right BC
-0.09 0.54 -0.25 0.11 -0.21 0.17
Dependent variables: summed stress score (SSS); summed rest score (SRS);
anterior wall stress score (ASSS)
The analysis was performed after controlling for hypertension, hyperlipidemia
and family history of cardiovascular disease. BC: breast cancer patients; *: p ≤
0.05; **: p ≤ 0.01.
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that there is discrepancy between the above mentioned
studies and our case-control study as well as the other
prospective studies that showed myocardial imaging
abnormalities induced by radiotherapy [23-29], this is
probably not the case since the studies showing no
radiotoxicity had as endpoints either myocardial infarc-
tion [32] or mortality from ischemic heart disease [19]
and most studies showing radiotoxicity as our study
concern only abnormal imaging but insignificant clinical
consequences.
An important finding in our study is that even clini-
cally silent, there were increased MPI abnormalities in
right BC patients after radiotherapy compared to con-
trols. The fact that in our study there was no statistical
significance between the left and right irradiated patients
suggest that that only comparison between right and left
sided irradiated BC patients [34] may not be enough to
accurately estimate cardiotoxicity since radiation to
either side may result in some MPI changes. Thus,
either prospective or case-control studies are probably
more reliable to assess the effects of radiotherapy in BC
patients.
Apart from possible radiation-induced toxic effects,
the heart and coronary vessels may be further compro-
mised in the BC patient by the use of anthracycline-con-
taining chemotherapy in the adjuvant therapy. In the
present study, no statistically significant cardiotoxicity
was detected in the patients that received adjuvant
anthracycline-based chemotherapy compared to patients
that did not receive such chemotherapy. In any event,
myocardial perfusion scintigraphy, may be an important
tool to detect possible myocardial perfusion alterations
after radiotherapy [35] or chemotherapy [36] in BC
patients.
Conclusion
The present study demonstrated that postoperative
radiation therapy for BC patients result in increased
MPI alterations compared to a control group of indivi-
duals that had myocardial SPECT for non-specific cardi-
ological complaints. The perfusion alterations although
more frequent in the patients that received radiation
therapy to the left breast they are also apparent in
patients that received radiation to the right breast. How-
ever, the clinical consequences of the detected SPECT
abnormalities remained unknown and probably insignifi-
cant. In any event, asymptomatic BC patients that exhi-
bit a moderately pathologic MPI could be considered
for coronary risk factor modification in addition to close
observation. Future clinical trials to further assess the
toxicity of radiation therapy for BC patients should be
prospective or case control studies and not simply com-
paring toxicity from radiation to left and right side since
both therapies may result in some degree of myocardial
toxicity.
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